J&J Wins FDA Nod for Erleada, the First Drug for Nonmetastatic Prostate Cancer Post author:Sam Post published:February 14, 2018 Post category:BioPharma Janssen got a little love from the FDA on Wednesday. Source: BioSpace You Might Also Like Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Years Of Follow-Up June 4, 2017 Ignyta To Present At 2016 Healthcare Conference July 8, 2016 AbbVie and Voyager Therapeutics Launch $1.2 Billion+ Alzheimer’s Partnership February 19, 2018
Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Years Of Follow-Up June 4, 2017
